

合剤はMI後治療へのアドヒアランスを上昇させる (Presentation #5917)

FOCUS:新たな治療体制はより多くの患者が2度目の心筋梗塞を発症するのを予防するのに有望である

FOCUS: Novel treatment regime has potential to prevent more patients having a second heart attack

新たな合剤は心筋梗塞(MI)後治療へのアドヒアランスを上昇させるとのスタディ結果が2014年European Society of Cardiology Congressホットラインセッションで発表された。FOCUS2はMI後患者における固定用量の組み合わせ(アセチルサリチル酸[ASA]100mg、シンバスタチン40mg、ラムプリル2.5、5、または10mgを含むCNIC-FS (3)-FERRER合剤)へのアドヒアランスおよび心血管リスクファクターのコントロールに対する効果を調査した。計695人の患者が合剤または3剤を別々に内服する群にランダムに割り付けられ、9か月間追跡された。患者は合剤として与えられた方が3剤別々の錠剤として与えられた場合よりもMI予防の薬剤を内服する確率が高かった。このスタディでは2つの方法を用いた。自己申告のアンケートでは、合剤群の患者の68%が薬を内服していたのに比べ、3剤内服群では59%だけであった。錠数を確認すると、合剤群の92%の患者が内服を順守したのに対し、別々に内服した群では84%であった。この新たな治療体制は患者が2度目のMIを発症するのを軽減する可能性がある。

Full Text

A new polypill increases adherence to treatment following a myocardial infarction (MI), according to results from the FOCUS Study presented for the first time at ESC Congress 2014. The novel treatment regime has the potential to prevent more patients having a second heart attack.

Dr. Valentin Fuster, MD, PhD, was lead author on the study. He is physician-in-chief at The Mount Sinai Hospital and director of Mount Sinai Heart, The Mount Sinai Health System, New York, US.

Dr. Fuster said "Despite continuous advances in all areas of cardiovascular (CV) medicine, cardiovascular disease (CVD) has steadily increased in prevalence to become the number one cause of death worldwide. It is estimated that half of the overall reduction in CVD mortality observed over the past 20 years in western countries could be attributed to appropriate use of CV medications for secondary prevention. But lack of adherence to treatment impedes adequate secondary prevention and contributes to the CVD pandemic."

He continued: "The most important factors responsible for a lack of adherence to treatment are the complexity of treatment and the daily number of prescribed pills. The idea of using a polypill for CVD prevention has gained increasing momentum because it could increase adherence and therefore contain the progression of CVD. A polypill could simplify healthcare delivery, improve cost-effectiveness, support the comprehensive prescription of evidence-based cardioprotective drugs, and reach underdeveloped regions of the world."

The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention (FOCUS 2) study was established to investigate adherence to secondary prevention medication and test a new polypill. The study was conducted in two subsequent phases. FOCUS 1 included post MI patients in a multi-country comprehensive analysis of socioeconomic, comorbidity, and other factors that determine adherence to CV medications. FOCUS 2 was a randomized controlled clinical trial testing the effect of a fixed-dose combination (FDC), the CNIC-FS (3)-FERRER polypill, containing acetylsalicylic acid (ASA) 100 mg, simvastatin 40 mg and ramipril 2.5, 5 or 10 mg, on adherence and control of CV risk factors in post MI patients.

FOCUS 1 included 2 118 patients with a history of MI from five different countries (Spain, Italy, Argentina, Brazil and Paraguay). The degree of adherence to prescribed medications was calculated using the Morisky Green Adherence Questionnaire, a self-reported method with four questions on adherence behavior. The researchers found an average baseline adherence level of 45.5%.

The researchers also conducted a descriptive analysis of variables that impede adequate adherence. They found that patients below 50 years of age, those taking more than 10 pills, following a complex regimen (i.e. those taking medications other than orally), current smokers and those with sedentary lifestyles were significantly more non-adherent.

Dr. Fuster said "Importantly, there was a significant trend towards more non-adherence with a higher score of depression (as measured by the PHQ-9 questionnaire). Of the socio-demographic variables, illiteracy level, lower social support and lower percentage of insurance cover showed significantly lower levels of adherence as well as those patients being treated by general practitioners (as opposed to cardiologists) and being treated in a private center (as opposed to a public health center)."

In a stepwise forward regression model, FOCUS 1 found that the risk of being non-adherent was independently associated with younger age (under 50 years old), scoring high on the depression scale, and following a complex (administrations other than oral) treatment. On the other hand, the odds of being adherent increased with higher percentage of health insurance coverage, and with optimal levels of social support.

In FOCUS 2, a total of 695 patients were enrolled from four countries and followed for a period of nine months. Patients were randomized to receive either the polypill or the three drugs separately. Adherence was measured with two methods: self-reported adherence using the Morisky Green Adherence Questionnaire as well as a direct method, the pill count.

Dr. Fuster said "Patients were more likely to take their medication to prevent a heart attack when it was given as a polypill, rather than as three separate pills. We found this using two methods. With the self-reported questionnaire, 68% of patients in the polypill group took their drugs compared to just 59% of patients in the group assigned to three drugs. With the pill count, we found that 92% of patients in the polypill group were adherent compared to only 84% in the group assigned to separate drugs."

He added: "FOCUS 1 has identified the reasons that impede appropriate adherence to CV medications in a post MI population from five different countries. FOCUS 2 has shown that, compared with the three drugs given separately, the use of a polypill strategy significantly increases self-reported and directly measured medication adherence for secondary prevention following an acute MI. FOCUS 2 is ongoing and will assess whether there are any differences between the two treatment arms in blood pressure, blood cholesterol, safety or costs."

Dr. Fuster concluded "Our results suggest that the polypill has the potential to prevent more patients having a second heart attack. A randomized trial is needed to test whether the improved adherence with the polypill found in FOCUS results in fewer post MI patients having another MI."

Dr. Valentin Fuster, MD, PhD, is physician-in-chief at The Mount Sinai Hospital and director of Mount Sinai Heart, The Mount Sinai Health System, New York, US. He is also general director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, Spain.

FOCUS was funded by the 7th Framework Programme of the European Commission.

Conference News

[News 01]

薬剤によりいくつかの術後合併症が減少する

[News 02]

MI後のdarapladib投与はその後のリスクを低下させない

[News 03]

新しいクラスの薬剤は心不全においてACE阻害薬よりも優れている

[News 04]

Serelaxinは心不全の院内増悪を軽減する

[News 05]

完全血行再建術はMI後の予後を改善する

[News 06]

4極リードによりCRT合併症が減少する

[News 07]

CRTにおいて代替のリード位置は安全である

[News 08]

新たな生分解性の薄いステントは有望であることが示された

[News 09]

血行再建術を回避しても安全な患者の見極め

[News 10]

試験薬はスタチンと共に作用しコレステロールを低下させる

[News 11]

糖尿病患者においてロスバスタチンはアトルバスタチンよりも選択肢として優れている可能性がある

[News 12]

ロスバスタチンは冠動脈内プラーク体積を縮小させる

[News 13]

アミオダロンはアブレーション後の短期回復を改善する

[News 14]

リバーロキサバンを用いた前治療により除細動が早められる可能性がある

[News 15]

鉄の経静脈的補給は心不全症状を改善する

[News 16]

合剤はMI後治療へのアドヒアランスを上昇させる